Sarissa Consulting’s Turning Point Therapeutics TPTX Stock Holding History
Bought
Maintained
Sold
Sarissa Consulting's TPTX Position: Q3 2022 in Review
Sarissa Consulting sold out of Turning Point Therapeutics (TPTX) in Q3 2022, closing a stake of 12,000 shares — an estimated $903K sold.
Sarissa Consulting first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $903K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Sarissa Consulting reported no remaining Turning Point Therapeutics position as of Q3 2022 after selling out during the quarter.
- Sarissa Consulting sold 12,000 Turning Point Therapeutics shares in Q3 2022, an estimated $903K.
- Sarissa Consulting first reported a position in Turning Point Therapeutics in Q2 2022 and held it in 1 quarter.
- Sarissa Consulting's Turning Point Therapeutics position peaked at $903K in Q2 2022.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics as of Q3 2022.
Based on Sarissa Consulting's 13F filing for Q3 2022, filed 14 Nov 2022.